VGXI, Inc. today announced the execution of a Master Product Sale Agreement to supply plasmid between its parent company, VGX International, and BioCancell Therapeutics. BioCancell is a biopharmaceuticals corporation specializing in the development of Patient-Oriented, Targeted Therapy for the treatment of numerous types of cancer. Products under the Agreement will be manufactured at the VGXI, Inc production facility in The Woodlands, TX.
Henry Hebel, Chief Operating Officer of VGXI said, “We are pleased to have a partner with such an impressive platform technology. BioCancell has a track record of generating clinical results. We look forward to the possibility of supporting multiple clinical indications of this critical work.”
Avi Barak, CEO of BioCancell Therapeutics, added, “A company developing revolutionary drugs for various types of cancer relies on its manufacturers for product quality, which is a function of the technologies and advanced services they offer. It is for this reason that we chose to work with VGXI as we move on to plan clinical trials for additional cancer types, requiring the highest manufacturing standards.”
BioCancell Therapeutics Inc. is a biotechnology company specializing in the development of Patient-Oriented, Targeted Therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology constitutes a novel ‘search and destroy’ paradigm for the targeted destruction of cancer cells – with no effect on surrounding tissue and no observed side effects – for long-term, safe treatment and prevention of cancer.
BioCancell was co-founded in 2004 by Professor Avraham Hochberg, Professor of Molecular Biology at the Hebrew University of Jerusalem, based on technology he has developed over the past 15 years. Between 2006-2008, BioCancell has successfully completed private rounds of funding and an initial public offering totaling $12.5 million. Its securities are traded on the Tel Aviv Stock Exchange, with the major stockholders being Cal Biotechnology Industries, a member of the IDB group of companies, and Prof. Hochberg. For more information, please visit www.biocancell.com.
About VGXI Inc.
VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. The Company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for client companies’ clinical studies in the US and Europe, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. This rapid turnaround program provides consistent materials to build a reliable pre-clinical dataset. For information, visit 126.96.36.199/~vgxiico2
Cautionary Factors That May Affect Future Results
Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations.Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.